Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Allarity Therapeutics (ALLR) Net Income towards Common Stockholders (2024 - 2025)

Allarity Therapeutics' Net Income towards Common Stockholders history spans 2 years, with the latest figure at -$3.4 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 54.74% year-over-year to -$3.4 million; the TTM value through Dec 2025 reached -$11.2 million, up 55.35%, while the annual FY2025 figure was -$11.2 million, 55.35% up from the prior year.
  • Net Income towards Common Stockholders reached -$3.4 million in Q4 2025 per ALLR's latest filing, down from -$2.8 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.7 million in Q2 2024 to a low of -$12.2 million in Q3 2024.